|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Hepatitis B in patients with hematological diseases: An update显示文摘Hepatitis B virus(HBV) reactivation(HBVr) in patients undergoing immunosuppressive therapy is still a hot topic worldwide. Its prevention and management still represents a challenge for specialists dealing with immunosuppressed patients. Aim of this paper is to provide a critical review of the relevant information emerged in the recent literature regarding HBV reactivation following immunosuppressive treatments for oncohematological tumors. A computerized literature search in MEDLINE was performed using appropriate terms arrangement, including English-written literature only or additional relevant articles. Articles published only in abstract form and case reports not giving considerable news were excluded. Clinical manifestation of HBVr can be manifold, ranging from asymptomatic self-limiting anicteric hepatitis to life-threatening fulminant liver failure. In clusters of patients adverse outcomes are potentially predictable. Clinicians should be aware of the inherent risk of HBVr among the different virological categories(active carriers, occult HBV carriers and inactive carriers, the most intriguing category), and classes of immunosuppressive drugs. We recommend that patients undergoing immunosuppressive treatments for hematological malignancies should undergo HBV screening. In case of serological sign(s) of current or past infection with the virus, appropriate therapeutic or preventive strategies are suggested, according to both virological categories, risk of HBVr by immunosuppressive drugsand liver status. Either antiviral drug management and surveillance and pre-emptive approach are examined, commenting the current international recommendations about this debated issue. | Chiara Coluccio Paola Begini Alfredo Marzano Adriano Pellicelli Barbara Imperatrice Giulia Anania Gianfranco Delle Fave Massimo Marignani | 2017 | World Journal of Hepatology2017，9，25： | 5 |
| 2 | Hepatitis C virus-related B cell subtypes in non Hodgkin's lymphoma显示文摘AIM:To evaluate if indolent B cell-non Hodgkin's lymphoma(B-NHL) and diffuse large B-cell lymphoma(DLBCL) in hepatitis C virus(HCV) positive patients could have different biological and clinical characteristics requiring different management strategies.METHODS:A group of 24 HCV related B-NHL patients(11 indolent,13 DLBCL) in whom the biological and clinical characteristics were described and confronted.Patients with DLBCL were managed with the standard of care of treatment.Patients with indolent HCV-related B-NHL were managed with antiviral treatment pegylated interferon plus ribavirin and their course observed.The outcomes of the different approaches were compared.RESULTS:Patients with DLBCL had a shorter duration of HCV infection and a higher prevalence of HCV genotype 1 compared to patients with indolent B-NHL in which HCV genotype 2 was the more frequent genotype.Five of the 9 patients with indolent HCV-relatedB-NHL treated with only antiviral therapy,achieved a complete response of their onco-haematological disease(55%).Seven of the 13 DLBCL patients treated with immunochemotheraphy obtained a complete response(54%).CONCLUSION:HCV genotypes and duration of HCV infection differed between B-NHL subtypes.Indolent lymphomas can be managed with antiviral treatment,while DLBCL is not affected by the HCV infection. | Adriano M Pellicelli Massimo Marignani Valerio Zoli Mario Romano Aldo Morrone Lorenzo Nosotti Giuseppe Barbaro Antonio Picardi Umberto Vespasiani Gentilucci Daniele Remotti Cecilia D'Ambrosio Caterina Furlan Fabrizio Mecenate Ettore Mazzoni Ignazio Majolino Roberto Villani Arnaldo Andreoli Giorgio Barbarini | 2011 | World Journal of Hepatology2011，3，11： | 4 |
| 3 | Non-cirrhotic portal hypertension with large regenerative nodules: A diagnostic challenge显示文摘Non-cirrhotic portal hypertension is a poorly understood condition characterized by portal hypertension in the absence of conventional hepatic cirrhosis and described in association with blood coagulation disorders, myeloproliferative and immunological diseases and with exposure to toxic drugs. Very recently, precise classification criteria have been proposed in order to define four distinct subcategories. The present case highlights how the clinical presentation, the confounding results from imaging studies, and the difficulties in the histological evaluation often render cases of non-cirrhotic portal hypertension a real diagnostic challenge. It also underscores the classification problems which can be faced once this diagnosis is performed. Indeed, the different subcategories proposed result from the prevalent subtypes in a spectrum of hepatic regenerative responses to a variety of injuries determining microcirculatory dis-turbances. More flexibility in classification should derive from this etiopathogenic background. | Umberto Vespasiani Gentilucci Paolo Gallo Giuseppe Perrone Riccardo Del Vescovo Giovanni Galati Sandro Spataro Chiara Mazzarelli Adriano Pellicelli Antonella Afeltra Antonio Picardi | 2011 | World Journal of Gastroenterology2011，17，20： | 2 |
| 4 | Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late显示文摘 | Adriano M. Pellicelli Marzia Montalbano Raffaella Lionetti Christine Durand Peter Ferenci Gianpiero D’Offizi Viola Knop Andrea Telese Ilaria Lenci Arnaldo Andreoli Stefan Zeuzem Mario Angelico | 2014 | Digestive and Liver Disease2014，，： | 2 |
| 5 | Alteration of left ventricular filling evaluated by Doppler echocardiography as a potential marker of acute rejection in orthotopic heart transplant显示文摘 | Pellicelli AM Cosial JB Ferranti E | 1996 | Angiology1996，3541，： | 1 |
| 6 | Clinical manifestation of HIV related pulmonary hypertension显示文摘 | PETROSILLO N PELLICELLI A M BOUMIS E | 2001 | Ann N Y Acad Sci2001，946，11： | 1 |
| 7 | Alteration of left ventricular filling evoluated by Doppler echocardiography as a potentical marker of acute reject in orthotopic heart transplant显示文摘 | Pellicelli AM Cosial JB Ferranti E | 1996 | Angiology1996，47，： | 1 |
| 8 | 查看详情显示文摘 | Ghidini M Asti G Pellicelli R | | 0，，： | 1 |
| 9 | Clinical manifestation of HIV related pulmonary hypertension显示文摘 | Petrosillo N Pellicelli A M BQumis E | 2001 | Ann N Y Acad Sci2001，946，11： | 1 |
| 10 | Role of ribavirin in hepatitis flare in HCV-infected patients with B cell non Hodgkin’s lymphoma treated with rituximab-containing regimens显示文摘 | Adriano M. Pellicelli | 2011 | Digestive and Liver Disease2011，，6： | 1 |
| 11 | 180 CLINICAL AND GENETIC FACTORS ASSOCIATED TO DEVELOPMENT OF PORTAL VEIN THROMBOSIS IN CIRRHOTIC PATIENTS WITHOUT HEPATOCELLULAR CARCINOMA显示文摘 | A.M. Pellicelli C. D’Ambrosio G. Barbaro R. Villani P. Guarascio L. Fondacaro A. Cortese M. Atzori G. Regine L. Adami R. Santoro G.M. Ettorre A. Andreoli | 2011 | Journal of Hepatology2011，，： | 1 |
| 12 | HIV-associated coronary arteritis in a patient with fatal myocardial infarction显示文摘 | Barbaro G Barbarini G Pellicelli AM | 2001 | N Engl J Med2001，344，23： | 1 |
| 13 | Long -term efficacy of interferon alpha -2b and lamivudine monotherapy in patients with chronic hepatitis B , An Italian multicenter, randomized trial 显示文摘 | Barharo G Zechini F Pellicelli AM | 2001 | J Hepatol2001，35，： | 1 |
| 14 | Magnetic phase diagram and demagnetization processes in perpendicular exchange - spring multilayers 显示文摘 | ASTI G GHIDINI M PELLICELLI R | 2006 | Phys Rev2006，73，09： | 1 |
| 15 | Pathogenesis of HIV-related pulmonary hypertension显示文摘 | Pellicelli A M Palmieri F Cicalini S | 2001 | Ann N Y Acad Sci2001，946，11： | 1 |
| 16 | Boceprevir or telaprevir in hepatitis C virus chronic infection:The Italian real life experience显示文摘AIM: To check the safety and efficacy of boceprevir/telaprevir with peginterferon/ribavirin for hepatitis C virus(HCV) genotype 1 in the real-world settings. METHODS: This study was a non-randomized, observational, prospective, multicenter. This study involved 47 centers in Italy. A database was prepared for the homogenous collection of the data, was used by all of the centers for data collection, and was updated continuously. All of the patients enrolled in this study were older than 18 years of age and were diagnosed with chronic infection due to HCV genotype 1. The HCV RNA testing was performed using COBAS-Taq Man2.0(Roche, LLQ 25 IU/m L). RESULTS: All consecutively treated patients were included. Forty-seven centers enrolled 834 patients as follows: Male 64%; median age 57(range 18-78), of whom 18.3% were over 65; mean body mass index 25.6(range 16-39); genotype 1b(79.4%); diagnosis of cirrhosis(38.2%); and fibrosis F3/4(71.2%). The following drugs were used: Telaprevir(66.2%) and PEG-IFN-alpha2a(67.6%). Patients were na?ve(24.4%), relapsers(30.5%), partial responders(14.8%) and null responders(30.3%). Overall, adverse events(AEs) occurred in 617 patients(73.9%) during the treatment. Anemia was the most frequent AE(52.9% of cases), especially in cirrhotic. The therapy was stopped for 14.6% of the patients because of adverse events or virological failure(15%). Sustained virological response was achieved in 62.7% of the cases, but was 43.8% in cirrhotic patients over 65 years of age. CONCLUSION: In everyday practice, triple therapy is safe but has moderate efficacy, especially for patients over 65 years of age, with advanced fibrosis, nonresponders to peginterferon + ribavirin. | Antonio Ascione Luigi Elio Adinolfi Pietro Amoroso Angelo Andriulli Orlando Armignacco Tiziana Ascione Sergio Babudieri Giorgio Barbarini Michele Brogna Francesco Cesario Vincenzo Citro Ernesto Claar Raffaele Cozzolongo Giuseppe D’Adamo Emilio D’Amico Pellegrino Dattolo Massimo De Luca Vincenzo De Maria Massimo De Siena Giuseppe De Vita Antonio Di Giacomo Rosanna De Marco Giorgio De Stefano Giulio De Stefano Sebastiano Di Salvo Raffaele Di Sarno Nunzia Farella Laura Felicioni Basilio Fimiani Luca Fontanella Giuseppe Foti Caterina Furlan Francesca Giancotti Giancarlo Giolitto Tiziana Gravina Barbara Guerrera Roberto Gulminetti Angelo Iacobellis Michele Imparato Angelo Iodice Vincenzo Iovinella Antonio Izzi Alfonso Liberti Pietro Leo Gennaro Lettieri Ileana Luppino Aldo Marrone Ettore Mazzoni Vincenzo Messina Roberto Monarca Vincenzo Narciso Lorenzo Nosotti Adriano Maria Pellicelli Alessandro Perrella Guido Piai Antonio Picardi Paola Pierri Grazia Pietromatera Francesco Resta Luca Rinaldi Mario Romano Angelo Rossini Maurizio Russello Grazia Russo Rodolfo Sacco Vincenzo Sangiovanni Antonio Schiano Antonio Sciambra Gaetano Scifo Filomena Simeone Annarita Sullo Pierluigi Tarquini Paolo Tundo Alfredo Vallone | 2016 | World Journal of Hepatology2016，8，22： | 1 |
| 17 | Long-term efficacy of interferon alpha - 2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B : an Italian multicenter, randomized trial 显示文摘 | Barbaro G Zechini F Pellicelli AM | 2001 | J Hepatol2001，35，： | 1 |
| 18 | Hardsoft composite magnets 显示文摘 | Ghidini M Asti G Pellicelli R Pemechele C Solzi M | 2007 | Journal of Magnetism and Magnetic Materials2007，316，： | 1 |
| 19 | Social Values and Ethics for Communicating the Corporate Identity显示文摘 | Cecilia Casalegno Chiara Civera Michela Pellicelli | 2012 | Chinese Business Review2012，11，7： | 1 |
| 20 | Adefovir and lamivudine in combination compared with adefovirmonotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine:a retrospective,multicenter,nonrandomized,open-label study显示文摘 | PELLICELLI A M BARBARO G FRANCAVILLA R | 2008 | Clin Ther2008，30，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员